113 POSTER Phase II trial to assess the activity of MVA5T4 (Trovax®) alone versus MVA5T4 plus granulocyte macrophage colony-stimulating factor (GM-CSF) in patients (pts) with progressive hormone refractory prostate cancer (HRPC)

✍ Scribed by R. Amato; M. Karediy; A. Cao; M. Khan; S. Naylor; M. McDonald; R. Harrop; W. Shingler; P. Chikoti; N. Drury

• Book ID: 118623742
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 61 KB
• Volume: 4
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(06)70119-7